Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment



Rating:

Share or cite this content

Citations should be made in the following way:
T. Luchnikova (Blagoveshchensk (Amur Oblast), Russian Federation), O. Prikhodko (Blagoveshchensk (Amur Oblast), Russian Federation), K. Fesyun (Khabarovsk, Russian Federation). Experience of using Janus kinase inhibitors in COVID-19. 2661

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020 Kinase inhibitors Source: Annual Congress 2012 - The promise of new drugs for treating asthma and COPD Year: 2012 LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 p38 MAPK inhibitors in COPD Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012 Role of p38 mitogen-activated protein kinase in trauma/hemorrhage and subsequent peumococcal pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 In-vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588 Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 JAK–STAT pathway activation in COPD Source: Eur Respir J 2015; 46: 843-845 Year: 2015 Phosphorylation of xanthine dehydrogenase/oxidase in hypoxia: role of p38 MAP kinase Source: Eur Respir J 2001; 18: Suppl. 33, 73s Year: 2001 Inhibition of phosphatidylinositol 3-kinase and mitogen-activated protein kinase kinase prevents malignant pleural mesothelioma cell growth Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010 Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs Source: Eur Respir J 2013; 42: 28-41 Year: 2013 Validation of AMP-activated protein kinase as a therapeutic target in bronchiectasis Source: ERS Lung Science Conference 2020 Year: 2020 Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease Source: Eur Respir Rev, 26 (146) 170061; 10.1183/16000617.0061-2017 Year: 2017 Effect of fudosteine on mucin production Source: Eur Respir J 2008; 32: 1195-1202 Year: 2008 A patient with a lazarus effect on tyrosine kinase inhibition Source: Virtual Congress 2020 – Lung cancer grand round Year: 2020 Transmission of muscarinic receptor mediated proliferative effects in human lung fibroblasts involves ERK-MAP kinase, but not PI-3 kinase and Rho-kinase pathway Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007 Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders Source: Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020 Year: 2020 Inhibition of p38 MAPK-dependent bronchial contraction after ozone by corticosteroids Source: Eur Respir J 2011; 37: 933-942 Year: 2011